A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs RO 5545965 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Roche
- 25 Jan 2014 New trial record